ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
ZIVO Bioscience (OTCQB: ZIVO) reports positive results from a University of Delaware study evaluating its proprietary active ingredients against Low Pathogenicity Avian Influenza (LPAI) in poultry. The two-part study showed statistically significant findings including reduced viral shedding in infected birds and delayed LPAI transmission when healthy birds were exposed to infected ones.
The study demonstrated that birds receiving ZIVO's ingredients experienced an early significant decrease in viral titers compared to untreated controls. Different product configurations showed varying effectiveness, with some better at lowering viral titer and others at slowing spread, suggesting potential for comprehensive protection through optimal product configuration.
ZIVO Bioscience (OTCQB: ZIVO) riporta risultati positivi da uno studio dell'Università del Delaware che valuta i suoi ingredienti attivi proprietari contro l'Influenza Aviaria a Bassa Patogenicità (LPAI) negli uccelli da cortile. Lo studio, diviso in due parti, ha mostrato risultati statisticamente significativi tra cui la riduzione dell'emissione virale negli uccelli infetti e il ritardo nella trasmissione della LPAI quando i polli sani venivano esposti a quelli infetti.
Lo studio ha dimostrato che gli uccelli che ricevevano gli ingredienti di ZIVO mostrano una significativa diminuzione precoce dei titoli virali rispetto ai controlli non trattati. Diverse configurazioni del prodotto hanno mostrato efficacia variabile, con alcune migliori nella riduzione del titolo virale e altre nel rallentare la diffusione, suggerendo un potenziale per una protezione complessiva tramite una configurazione ottimale del prodotto.
ZIVO Bioscience (OTCQB: ZIVO) informa sobre resultados positivos de un estudio de la Universidad de Delaware que evalúa sus ingredientes activos patentados contra la Influenza Aviar de Baja Patogenicidad (LPAI) en aves de corral. El estudio, dividido en dos partes, mostró resultados estadísticamente significativos, incluyendo la reducción de la excreción viral en aves infectadas y el retraso en la transmisión de LPAI cuando aves sanas fueron expuestas a aves infectadas.
El estudio demostró que las aves que recibieron los ingredientes de ZIVO experimentaron una disminución significativa temprana en los títulos virales en comparación con los controles no tratados. Diferentes configuraciones de producto mostraron variaciones en la efectividad, siendo algunas mejores para reducir el título viral y otras para ralentizar la propagación, sugiriendo un potencial para una protección integral a través de una configuración óptima del producto.
ZIVO Bioscience (OTCQB: ZIVO)는 델라웨어 대학교의 연구 결과, 자사의 독점 활성 성분이 가금류의 저병원성 조류 인플루엔자(LPAI)에 대한 효과를 평가한 긍정적인 결과를 보고했습니다. 두 부분으로 나뉜 연구는 감염된 새에서의 바이러스 배출 감소 및 건강한 새가 감염된 새에 노출되었을 때 LPAI 전파의 지연을 포함한 통계적으로 유의미한 결과를 보여주었습니다.
연구에 따르면 ZIVO의 성분을 받은 새는 치료되지 않은 대조군에 비해 바이러스 항체 수치가 초기부터 유의미하게 감소했습니다. 다양한 제품 구성은 효과가 다르게 나타나, 일부는 바이러스 수치를 낮추는 데 더 좋고 다른 일부는 전파를 늦추는 데 유리해, 최적의 제품 구성을 통해 포괄적인 보호 가능성을 시사합니다.
ZIVO Bioscience (OTCQB: ZIVO) fait état de résultats positifs d'une étude de l'Université du Delaware évaluant ses ingrédients actifs propriétaires contre l'Influenza Avirale à Faible Pathogénicité (LPAI) chez les volailles. L'étude en deux parties a montré des résultats statistiquement significatifs, y compris une réduction de l'excrétion virale chez les oiseaux infectés et un retard de la transmission de la LPAI lorsque des oiseaux sains étaient exposés à des oiseaux infectés.
L'étude a démontré que les oiseaux recevant les ingrédients de ZIVO ont connu une diminution précoce et significative des titres viraux par rapport aux témoins non traités. Différentes configurations de produits ont montré une efficacité variable, certaines étant meilleures pour réduire le titre viral et d'autres pour ralentir la propagation, suggérant un potentiel de protection globale grâce à une configuration optimale du produit.
ZIVO Bioscience (OTCQB: ZIVO) berichtet über positive Ergebnisse einer Studie der University of Delaware, die seine proprietären aktiven Inhaltsstoffe gegen die Low Pathogenicity Avian Influenza (LPAI) bei Geflügel bewertet. Die zweigeteilte Studie zeigte statistisch signifikante Ergebnisse, darunter eine verminderte Virusauscheidung bei infizierten Vögeln und eine verzögerte Übertragung von LPAI, als gesunde Vögel mit infizierten Vögeln in Kontakt kamen.
Die Studie ergab, dass Vögel, die ZIVOs Inhaltsstoffe erhielten, im Vergleich zu unbehandelten Kontrollen einen frühzeitigen signifikanten Rückgang der Virus-Titer zeigten. Verschiedene Produktkonfigurationen wiesen unterschiedliche Wirksamkeiten auf, wobei einige besser beim Senken der Virus-Titer und andere beim Verlangsamen der Ausbreitung abschnitten, was auf das Potenzial für einen umfassenden Schutz durch eine optimale Produktkonfiguration hinweist.
- Statistically significant reduction in viral titers in infected birds receiving ZIVO's products
- Demonstrated delay in LPAI transmission between healthy and infected birds
- Products showed potential as preventative measures for reducing LPAI spread in commercial poultry operations
- Multiple product configurations identified with different effectiveness profiles
- End-of-study viral decrease was not statistically significant
- Additional studies needed before commercialization
- Different products showed varying effectiveness, indicating no single solution addresses all aspects
Key findings of statistical significance from the study include:
- A reduction in viral titers (viral shedding) in infected birds receiving ZIVO’s products compared with untreated infected controls.
- A delay in transmission of LPAI when healthy birds were exposed to infected birds, suggesting a slower and less aggressive spread of disease.
The two-part controlled study evaluated the efficacy of ZIVO’s proprietary active ingredients, previously shown to be efficacious for mitigating the effects of coccidiosis in broiler chickens, against LPAI.
In the first part of the study, infected birds receiving a mixture of ZIVO’s proprietary active ingredients showed an early significant decrease in viral titers compared with untreated, infected controls, thereby reducing amount of detectable virus that was shed. At the end of the study, although not significant in nature, a numerical decrease in virus was noted in birds receiving ZIVO’s product. In the second part, healthy chickens were housed with infected birds, replicating a real-world, high-risk environment for disease transmission. Compared to an untreated control group, birds that received ZIVO’s proprietary active ingredients that were housed with infected birds experienced a statistically significant delay in viral detection. This observed delay suggests that ZIVO’s products limit viral replication within a host.
These favorable results indicate that ZIVO’s proprietary active ingredients represent potential preventative measures for reducing the spread of LPAIV in commercial poultry operations and enhancing overall flock health.
Multiple products were explored to identify the most effective strategies against LPAI. While some products were better at lowering the viral titer, others were more effective at slowing the spread, suggesting that an optimal product configuration could provide more comprehensive protection. The study’s positive outcomes justify further research and product development, supporting the potential of ZIVO’s pipeline to address both LPAIV infections as well as a broad spectrum of other viral challenges faced by the poultry industry.
“We are highly encouraged by the outcomes of this study,” said John B. Payne, Chairman and CEO of ZIVO Bioscience. “The University of Delaware’s findings provide compelling evidence that our feed ingredients could be valuable tools in mitigating the risk of avian influenza outbreaks without the limitations associated with vaccines. Reducing disease transmission can positively impact both animal welfare and the operations of producers. These study results represent a significant milestone in our efforts to deliver science-driven, sustainable solutions to address serious challenges facing the global poultry industry.”
“This study sponsored by ZIVO Bioscience enabled us to evaluate novel interventions to provide immune support for poultry,” said Brian Ladman, Ph.D., Principal Investigator at the University of Delaware’s Department of Animal and Food Sciences. “The findings demonstrate that further investigation into ZIVO’s active ingredients to safeguard poultry flocks against viral outbreaks is warranted. I look forward to continuing to work with ZIVO to identify novel solutions to this critical public health issue.”
“With these preliminary efficacy results, we are now planning additional studies to further evaluate the benefits of our products. We are at a critical point in our mission to find a viable treatment for avian influenza, and the need for an effective therapy grows every day,” said John Payne. “We will continue towards commercialization of our coccidiosis treatment while utilizing these preliminary results to further our partnership dialogues. I am confident that ZIVO can take the next step toward evaluating this potential breakthrough technology.”
About ZIVO Bioscience
Zivo Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.
Forward Looking Statements
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected time frame for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet our expected demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241220941955/en/
ZIVO Bioscience
Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130
kmarchiando@zivobioscience.com
Alliance Advisors IR
Tirth T. Patel
(212) 201-6614
tpatel@allianceadvisors.com
Source: Zivo Bioscience, Inc.
FAQ
What were the key findings of ZIVO's avian influenza study?
How did ZIVO's ingredients perform in reducing LPAI viral transmission?
What is the commercial potential of ZIVO's LPAI treatment?
How does ZIVO's LPAI treatment differ in effectiveness across product configurations?
